Asthalin (salbutamol sulfate) is a fast-acting, selective beta2-adrenergic receptor agonist bronchodilator indicated for the treatment and prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma and chronic obstructive pulmonary disease (COPD). Its primary mechanism of action involves relaxation of smooth muscle in the airways, leading to rapid opening of bronchial passages, decreased airway resistance, and improved airflow within minutes of administration. Available in multiple formulations including metered-dose inhalers (MDI), dry powder inhalers (DPI), nebulizer solutions, and tablets, Asthalin represents a cornerstone therapy in both rescue and maintenance management of obstructive pulmonary conditions.

Features

• Contains salbutamol sulfate as the active pharmaceutical ingredient (API)
• Available in metered-dose inhaler (100 mcg per puff), dry powder inhaler (200 mcg per dose), nebulizer solution (2.5 mg/2.5 mL and 5 mg/2.5 mL), and tablet (2 mg and 4 mg) formulations
• Rapid onset of action, typically within 5 minutes for inhalation routes
• Duration of bronchodilator effect lasts 4 to 6 hours
• Selective beta2-adrenergic agonist with minimal cardiac effects at therapeutic doses
• Portable and discreet delivery systems for emergency use
• Compatible with spacer devices for improved drug delivery
• Temperature-stable formulations requiring no refrigeration

Benefits

• Provides rapid relief from acute bronchospasm and asthma attacks within minutes of administration
• Effectively reverses exercise-induced bronchoconstriction when used prophylactically
• Reduces airway resistance and improves forced expiratory volume (FEV1) measurements
• Enables patients to maintain normal physical activity and quality of life
• Multiple delivery systems allow for personalized treatment approaches based on patient age, coordination, and severity
• Demonstrated safety profile with extensive clinical use spanning decades

Common use

Asthalin is primarily indicated for the relief of bronchospasm in conditions characterized by reversible airway obstruction. This includes acute asthma attacks, exercise-induced bronchoconstriction, and bronchospasm associated with chronic obstructive pulmonary disease (COPD). Healthcare providers frequently prescribe Asthalin as a rescue medication for immediate symptom relief during exacerbations. Additionally, it may be used prophylactically before anticipated exposure to known triggers such as exercise, cold air, or allergens. The medication is suitable for both pediatric and adult populations, with dosage adjustments based on age, severity, and formulation.

Dosage and direction

Metered-Dose Inhaler (100 mcg/puff): Adults and children 4 years and older: 1-2 puffs every 4-6 hours as needed for bronchospasm. Maximum: 8 puffs in 24 hours. Dry Powder Inhaler (200 mcg/dose): Adults and children 4 years and older: 1 inhalation every 4-6 hours. Maximum: 4 inhalations in 24 hours. Nebulizer Solution: Adults and children 12 years and older: 2.5 mg three to four times daily as needed. Children 2-12 years: 0.1-0.15 mg/kg per dose (minimum 1.25 mg, maximum 2.5 mg) three to four times daily. Tablets: Adults and children 12 years and older: 2-4 mg three to four times daily. Maximum: 32 mg daily. Children 6-12 years: 2 mg three to four times daily. Maximum: 24 mg daily.

Administer inhalation formulations with proper technique: shake canister well before use, exhale completely, place mouthpiece in mouth, activate while breathing in slowly and deeply, hold breath for 10 seconds, then exhale slowly. Wait one minute before second puff if prescribed. Rinse mouth after use to reduce systemic absorption and potential side effects.

Precautions

Use with caution in patients with cardiovascular disorders (hypertension, arrhythmias, coronary insufficiency), diabetes mellitus, hyperthyroidism, convulsive disorders, or hypersensitivity to sympathomimetic amines. Monitor serum potassium levels as beta2-agonists may cause transient hypokalemia. Paradoxical bronchospasm may occur; discontinue immediately if this develops. Excessive use may indicate deteriorating asthma control requiring reassessment of therapy. Not recommended as sole therapy for patients with frequent symptoms (more than twice weekly), who should receive anti-inflammatory maintenance treatment. Pregnancy Category C: use only if potential benefit justifies potential risk to fetus.

Contraindications

Hypersensitivity to salbutamol sulfate or any component of the formulation. Tachyarrhythmias. There are no other absolute contraindications when used as directed for life-threatening bronchospasm, though relative contraindications include known hypersensitivity to sympathomimetic amines, severe cardiac disease, and uncontrolled hypertension.

Possible side effect

Common side effects (>1%): tremor, headache, tachycardia, palpitations, muscle cramps, nervousness, dizziness, throat irritation, cough. Less common side effects: hypokalemia, hyperglycemia, paradoxical bronchospasm, restlessness, insomnia, nausea, vomiting. Rare side effects: allergic reactions including angioedema, urticaria, bronchospasm, hypotension, and collapse. Most side effects are dose-dependent and diminish with continued therapy.

Drug interaction

Beta-blockers (including ophthalmic preparations) may antagonize bronchodilating effects and produce severe bronchospasm in asthmatic patients. Concomitant use with other sympathomimetic agents may potentiate cardiovascular effects. May enhance hypokalemic effect of xanthine derivatives, steroids, diuretics. MAO inhibitors and tricyclic antidepressants may potentiate cardiovascular effects. Use with halogenated hydrocarbon anesthetics may increase risk of ventricular arrhythmias.

Missed dose

As Asthalin is typically used as needed for symptom relief, missed dose protocols do not generally apply. For scheduled maintenance dosing, if a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double doses to make up for a missed dose.

Overdose

Overdose may produce exaggeration of known pharmacologic effects: angina pain, hypertension, hypokalemia, seizures, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may occur following overdose. Treatment is supportive and symptomatic. Cardiac monitoring is recommended. Consider cardioselective beta-blockers cautiously in patients with bronchospastic disease. Dialysis is not appropriate.

Storage

Store at room temperature (15-30°C/59-86°F). Avoid excessive heat (above 40°C/104°F) and freezing. Keep canister away from open flame or heated surfaces as contents are under pressure. Do not puncture or incinerate. Protect from direct sunlight. Keep in original container with cap tightly closed. For nebulizer solutions: use within one month of opening and discard any unused portion. Keep out of reach of children.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting, changing, or stopping any medication. The prescribing physician should be aware of the complete medical history of the patient. Do not exceed recommended dosages. Individual responses to medication may vary. Proper inhaler technique is essential for effective therapy and should be regularly reviewed with healthcare providers.

Reviews

“Asthalin has been my rescue medication for over 15 years. As an emergency physician with asthma, I appreciate its rapid onset and reliability during acute exacerbations. The metered-dose inhaler provides consistent dosing when technique is proper.” - Dr. Eleanor R., Pulmonologist

“After trying multiple bronchodilators, Asthalin nebulizer solution has provided the most consistent relief for my pediatric patients with acute asthma exacerbations. The 2.5 mg formulation allows for precise weight-based dosing in children.” - Pediatric Respiratory Therapist

“As a COPD patient for 20 years, Asthalin MDI has been indispensable for managing sudden breathlessness. Its portability means I can maintain an active lifestyle with confidence, knowing relief is immediately available when needed.” - Clinical Trial Participant